Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 4/20 | 0.72 |
| ▸ | CYSLTR2 | Q9NS75 | 14/20 | 0.66 |
| ▸ | CYSLTR1 | Q9Y271 | 14/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | PPARG | P37231 | 2/20 | 0.65 |
| ▸ | PPARD | Q03181 | 2/20 | 0.65 |
| ▸ | PPARA | Q07869 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10690212 | 0.99 | GRM2 (0.71) | GRM2CYSLTR2CYSLTR1LMNAPPARG | |
| SCHEMBL9381009 | 0.99 | GRM2 (0.71) | GRM2CYSLTR2CYSLTR1LMNAPPARG | |
| SCHEMBL11041690 | 0.99 | GRM2 (0.71) | GRM2CYSLTR2CYSLTR1LMNAPPARG | |
| SCHEMBL4343526 | 0.96 | PPARG (0.67) | GRM2CYSLTR2CYSLTR1LMNAPPARG | |
| SCHEMBL4915595 | 0.92 | PPARG (0.65) | GRM2CYSLTR2CYSLTR1LMNAPPARG | |
| SCHEMBL10690507 | 0.91 | CYSLTR2 (0.69) | GRM2CYSLTR2CYSLTR1LMNAPPARG | |
| SCHEMBL10702435 | 0.91 | GRM2 (0.73) | GRM2CYSLTR2CYSLTR1LMNAPPARG | |
| SCHEMBL10522351 | 0.89 | CYSLTR2 (0.72) | GRM2CYSLTR2CYSLTR1LMNAPPARG | |
| SCHEMBL6247680 | 0.89 | PPARG (0.75) | GRM2CYSLTR2CYSLTR1LMNAPPARG | |
| SCHEMBL6938386 | 0.88 | GRM2 (0.58) | GRM2CYSLTR2CYSLTR1LMNAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288346-A1 | Acetophenone potentiators of metabotropic glutamate receptors | MERCK & CO., INC. | 2005-12-29 | — | — | US | disclosed |
| EP-0888278-B1 | ANTIDIABETIC AGENTS | MERCK & CO INC (US) | 2003-07-23 | — | — | EP | disclosed |
| EP-1086079-B1 | DERIVATIVES OF HYDROXYPHENYLSULFANYLBENZOIC AND HYDROXYPHENYLSULFANYLARYLACETIC ACIDS | LECIVA A S (CZ) | 2003-05-07 | — | — | EP | disclosed |
| US-6303612-B1 | USED AS ANTIINFLAMMATORY AND/OR ANTIASTHMATIC AGENTS | LECIVA, A.S. (CZ) | 2001-10-16 | — | — | US | disclosed |
| EP-1086079-A1 | DERIVATIVES OF HYDROXYPHENYLSULFANYLBENZOIC AND HYDROXYPHENYLSULFANYLARYLACETIC ACIDS | Leciva, A.S. (CZ) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999067208-A1 | DERIVATIVES OF HYDROXYPHENYLSULFANYLBENZOIC AND HYDROXYPHENYLSULFANYLARYLACETIC ACIDS | LECIVA, A.S. (CZ) | 1999-12-29 | — | — | WO | disclosed |
| EP-0888278-A4 | ANTIDIABETIC AGENTS | MERCK & CO INC (US) | 1999-06-30 | — | — | EP | disclosed |
| EP-0888278-A1 | ANTIDIABETIC AGENTS | Merck & Co., Inc. (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997028115-A1 | ANTIDIABETIC AGENTS | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |
| EP-0181779-B1 | Heterocyclic compounds, their production, and medicaments containing them | YAMANOUCHI PHARMA CO LTD (JP) | 1994-03-16 | — | — | EP | disclosed |
| US-4808729-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS | G. D. SEARLE & CO. (US) | 1989-02-28 | — | — | US | disclosed |
| EP-0303478-A1 | Improvements in or relating to leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1989-02-15 | — | — | EP | disclosed |
| US-4769482-A | Cyano and thiocyano intermediates | ELI LILLY AND COMPANY (US) | 1988-09-06 | — | — | US | disclosed |
| EP-0108592-B1 | LEUKOTRIENE ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1987-09-30 | — | — | EP | disclosed |
| US-4661505-A | 4-(4-ACETYL-3-HYDROXY-2-PROPYLPHENOXY) ALKANOIC ACIDS, TETRAZOLES, AND DERIVATIVES | ELI LILLY AND COMPANY (US) | 1987-04-28 | — | — | US | disclosed |
| EP-0131221-B1 | THIOETHERS, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS | Roche Diagnostics GmbH (DE) | 1987-01-28 | — | — | EP | disclosed |
| US-4621098-A | Thioethers and pharmaceutical compositions containing them | BOEHRINGER MANNHEIM GMBH (DE) | 1986-11-04 | — | — | US | disclosed |
| EP-0181779-A1 | Heterocyclic compounds, their production, and medicaments containing them | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1986-05-21 | — | — | EP | disclosed |
| EP-0131221-A2 | Thioethers, process for their preparation and medicines containing these compounds | Roche Diagnostics GmbH (DE) | 1985-01-16 | — | — | EP | disclosed |
| EP-0108592-A1 | Leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1984-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288346-A1 | Acetophenone potentiators of metabotropic glutamate receptors | GRM2, GRM1, GRIK2 | GRM2 1/4885CYSLTR2 357/4885CYSLTR1 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.